ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
AKBLF Stock Chart & Stats
$33.25
-$2.05(-9.17%)
At close: 4:00 PM EST
$33.25
-$2.05(-9.17%)
Day’s Range― - ―
52-Week Range$20.95 - $37.80
Previous CloseN/A
Volume1.00
Average Volume (3M)33.00
Market Cap
$7.46B
Enterprise Value$41.49B
Total Cash (Recent Filing)$316.00M
Total Debt (Recent Filing)$990.00M
Price to Earnings (P/E)42.3
Beta0.54
Next Earnings
May 05, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding202,567,200
10 Day Avg. Volume100
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap5.56
Enterprise Value/Revenue7.27
Enterprise Value/Gross Profit11.28
Enterprise Value/Ebitda26.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ALK-abello News
AKBLF FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest stock price was $20.95 and its highest was $37.80 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is $7.46B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is May 05, 2026 which is in 21 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on Feb 20, 2026. The company reported $0.189 earnings per share for the quarter, missing the consensus estimate of $0.205 by -$0.016.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Overvalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B pays a Annually dividend of $0.25 which represents an annual dividend yield of N/A. See more information on ALK-abello A/S Class B dividends here
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate is 0.27.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of $0.189 in its last earnings report, missing expectations of $0.205. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in AKBLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ALK-abello A/S Class B
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
AKBLF Company Deck
AKBLF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and financial year: double-digit revenue growth, meaningful EBIT margin expansion to 26%, positive cash conversion and clear commercial progress for tablets, pediatric rollouts and neffy early traction. The company also advanced its pipeline (peanut Phase II Fast Track) and broadened partnerships. Notable risks include margin mix headwinds in 2026 due to partner/ neffy sales, pricing/rebate pressures in Europe (France/Germany), supply/phasing constraints in Japan, and an R&D leadership change ahead of a material readout. Overall, the positives — robust growth, margin delivery, patient expansion and cash turnaround — outweigh the contained execution and mix risks laid out for 2026.View all AKBLF earnings summariesTechnical Analysis
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol-Myers Squibb
―
Ownership Overview
― Insiders
3.65% Mutual Funds
― Other Institutional Investors
91.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---